 |
Video: What is a Stock Split?
|
 |
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Co.'s therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Co.'s Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. According to our ARWR split history records, Arrowhead Pharmaceuticals has had 1 split. | |
 |

Arrowhead Pharmaceuticals (ARWR) has 1 split in our ARWR split history database. The split for ARWR took place on January 15, 2004. This was a 1 for 65 reverse split, meaning for each 65 shares of ARWR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 15.3846153846154 share position following the split.
When a company such as Arrowhead Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ARWR split history from start to finish, an original position size of 1000 shares would have turned into 15.3846153846154 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Arrowhead Pharmaceuticals shares, starting with a $10,000 purchase of ARWR, presented on a split-history-adjusted basis factoring in the complete ARWR split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/11/2015 |
|
End date: |
02/10/2025 |
|
Start price/share: |
$6.35 |
|
End price/share: |
$19.92 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
213.70% |
|
Average Annual Total Return: |
12.10% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$31,356.53 |
|
Years: |
10.01 |
|
|
 |
Date |
Ratio |
01/15/2004 | 1 for 65 |
|
 |